Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Open-Label Study of Taxoprexin (DHA-Paclitaxel) Injection by 2-Hour Intravenous Infusion in Patients With Metastatic Hormone-Refractory Prostate Cancer

NCT00024414 is registered in ClinicalTrials.gov with Theradex as lead sponsor.

NCT NCT00024414
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00024414 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Open-Label Study of Taxoprexin (DHA-Paclitaxel) Injection by 2-Hour Intravenous Infusion in Patients With Metastatic Hormone-Refractory Prostate Cancer
Lead sponsor
Theradex
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2001
Completion date
Not reported
Enrollment
Not reported
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer